Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 2210 • ACR Convergence 2022
Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study
Athimalaipet Ramanan¹, Pierre Quartier Dit Maire², Nami Okamoto³, Gabriella Meszaros⁴, Joana Araujo⁴, Zhongkai Wang⁴, Ran Liao⁴, Brenda Crowe⁴, Xin Zhang⁴, Rodney Decker⁴, Stuart Keller⁴, Hermine Brunner⁵ and Nicola Ruperto⁶, ¹Bristol Royal Hospital for Children, Bristol, United Kingdom, ²Necker hospital, Paris Cedex 15, France, ³Osaka Medical College, Takatsuki-city, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ⁶IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Baricitinib is a JAK1/2 selective inhibitor approved for the treatment of rheumatoid arthritis. Juvenile idiopathic arthritis (JIA) is a group of diseases characterized by…
Abstract Number: 0854 • ACR Convergence 2022
Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
Filipe Pinheiro¹, Mariana Leuzinger-Dias², Bruno Fernandes³, Diogo Fonseca⁴, Joana Vilaça⁵, Luís Figueira⁶ and Iva Brito⁷, ¹Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ²Ophtalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ³Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁴Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, ⁵Paediatrics Department, Hospital de Braga, Braga, Portugal, ⁶Ophthalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ⁷Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal
Background/Purpose: Uveitis is a frequent complication of juvenile idiopathic arthritis (JIA) and juvenile spondyloarthritis (jSpA), and diagnosis is often challenging. The importance of uveitis relates…
Abstract Number: 0876 • ACR Convergence 2022
Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis
Erin Balay¹ and Susan Shenoi², ¹University of Washington, Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Hospital and Research Center / University of Washington, Seattle, WA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatologic disease in children. JIA disease course and prognosis varies significantly between its seven categories, and…
Abstract Number: 2211 • ACR Convergence 2022
Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis
Amar Kumar¹, Joshua Tartarian², Valentina Shakhnovich³, Carl Langefeld⁴, Daniel Lovell⁵, Susan Thompson⁶, Mara Becker⁷ and Ryan Funk⁸, ¹University of Kansas, Kansas City, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Missouri-Kansas City School of Medicine & Children’s Mercy Kansas City, Kansas City, MO, ⁴Wake Forest School of Medicine, Winston Salem, NC, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ⁷Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, ⁸University of Kansas, Leawood, KS
Background/Purpose: Identification of disease and therapeutic biomarkers remains a barrier to the early diagnosis of and initiation of effective therapy for juvenile idiopathic arthritis (JIA).…
Abstract Number: 0855 • ACR Convergence 2022
Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Fenglong Xie¹, Timothy Beukelman¹, Jeffrey Curtis² and , for the CARRA Registry Investigators³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Hoover, AL, ³CARRA, Washington, DC
Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…
Abstract Number: 0877 • ACR Convergence 2022
Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis
Merav Heshin-Bekenstein¹, Szilvia Baron², Grant Schulert³, Anna Shusterman⁴, Rachel Shukrun⁴, Yoav Binenbaum⁴ and Ronit Elhasid⁵, ¹Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ²Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, causing significant morbidity. Despite the dramatic improvement in treatment, many patients…
Abstract Number: 2213 • ACR Convergence 2022
Multi-omic Analysis of Macrophage Activation Syndrome Associated with sJIA Reveals a Potential Role of Type I Interferons in the Expansion of Cycling T Cells
Kailey Brodeur¹, Liang Chen¹, zhengping huang², Yan Du¹, Holly Wobma³, Maria Taylor⁴, Joyce Chang³, Megan Day-Lewis³, Fatma Dedeoglu³, Olha Halyabar³, Mindy Lo³, Jane W. Newburger⁵, Mary Beth F. Son³, Robert Sundel³, Peter Nigrovic³, lauren henderson³ and Pui Lee³, ¹Boston Children's Hospital, Boston, MA, ²Guangdong Second Provincial Hospital, Guangzhou, China, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Brighton, MA, ⁵Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is a complication of systemic juvenile idiopathic arthritis (sJIA) characterized by cytokine storm and overt immune cell activation. We aim…
Abstract Number: 0856 • ACR Convergence 2022
A Cross-Sectional Description of Physical Activity (PA) in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Lori Tucker¹, Jaime Guzman², Lamia Hayawi³, Nick Barrowman³, Heather Macdonald⁴, Kristin Houghton⁵, David Cabral⁶, Bianca Lang⁷, Dax Rumsey⁸, Elizabeth Stringer⁹, Shirley Tse¹⁰, Roberta Berard¹¹, Claire Leblanc¹², Tommy Gerschman¹³, Liane Heale¹⁴, Karen Watanabe-Duffy¹⁵, Sarah Campillo¹², Natalie Shiff¹⁶ and Ciaran Duffy¹⁷, ¹British Columbia Children's Hospital, Vancouver, BC, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, ³Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Dalhousie University - Halifax, Halifax, NS, Canada, ⁸Stollery Children's Hospital, Edmonton, AB, Canada, ⁹IWK Hospital, Halifax, NS, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹London Health Sciences Centre, London, ON, Canada, ¹²McGill University, Montréal, QC, Canada, ¹³University of British Columbia - Vancouver, North Vancouver, BC, Canada, ¹⁴McMaster University, Oakville, ON, Canada, ¹⁵Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ¹⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, ¹⁷University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Participation in physical activity (PA) is a concern of children with JIA , however, factors associated with PA in these children are incompletely understood. …
Abstract Number: 0878 • ACR Convergence 2022
A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old
John Gibbons¹, Cynthia A. Kahlenberg¹, Deanna Jannat-Khah, DrPH, MSPH¹, Alexander B. Christ², Susan Goodman¹, Peter Sculco¹, Mark Figgie¹ and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Keck School of Medicine of USC, Los Angeles, CA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Total knee arthroplasty (TKA) is rarely performed in patients under 21 years old and may be performed in this population due to conditions such…
Abstract Number: PP08 • ACR Convergence 2022
Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
Ela Chintagunta¹, Courtney Wells² and Kristine Carandang³, ¹Young Patients' Autoimmune Research & Empowerment Alliance, Chicago, IL, ²University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA
Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of 13 when I was experiencing joint swelling in my lower body and my…
Abstract Number: 0858 • ACR Convergence 2022
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
Melissa Mannion¹, Chen Chen², Olha Halyabar³, Susan Paetkau⁴, Tingting Qiu⁵ and Bin Huang⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Cincinnati Children's Hospital Medical Center, Taipei, Taiwan, ³Children's Hospital/Boston Medical Center, Boston, MA, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cinciannati, OH
Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…
Abstract Number: 1097 • ACR Convergence 2022
Intrinsic STAT1 Deficiency Underlies Proinflammatory Imprint of Naive CD4+ T Cells in Spondyloarthritis
Bilade CHERQAOUI¹, Frederic Cremazy¹, Marc Lauraine¹, Ghazal Shammas², Roula Said-Nahal³, Hendrick Mambu Mambueni⁴, Felicie Costantino², Marine Fourmont², Simon Glatigny², Luiza Maria Araujo² and Maxime Breban², ¹INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, ²1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, ³Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, ⁴Genomic Platform of Faculty of Health Simone Veil - UVSQ university, Montigny-le-Bretonneux, France
Background/Purpose: Spondyloarthritis (SpA) development is associated with type 3 immune response activation. In HLA-B27/human β2-microglobulin transgenic rat model (B27-rat), this might at least be related…
Abstract Number: PP22 • ACR Convergence 2022
Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance
Natasha Trehan¹ and Laurie Proulx², ¹Take a Pain Check Foundation, Markham, ON, Canada, ²Canadian Arthritis Patient Alliance, Ottawa, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis is a chronic disease that affects a child's school life and relationships, creating social isolation for youth and young adults. Take…
Abstract Number: 0004 • ACR Convergence 2022
mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome
zhengping huang¹, xiaomeng You², Liang Chen³, Yan Du³, Kailey Brodeur³, Qiang Wang³, David Sykes⁴, Margaret Chang⁵, Julia Charles², Peter Nigrovic⁵ and Pui Lee⁵, ¹Guangdong Second Provincial Hospital, Guangzhou, China, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory syndrome characterized by fever, skin rash and arthritis. A subset of patients with sJIA develop…
Abstract Number: 0859 • ACR Convergence 2022
Systemic Juvenile Idiopathic Arthritis Associated Lung Disease in Europe
Claudia Bracaglia¹, Francesca Minoia², Christoph Kessel³, Sebastiaan Vastert⁴, Manuela Pardeo¹, Alessia Arduini¹, Ozge Basaran⁵, Nural kiper⁶, Mikhail Kostik⁷, Mia Glerup⁸, Sarka Fingerhutova⁹, Roberta Caorsi¹⁰, AnnaCarin Horne¹¹, Giovanni Filocamo¹², Helmut Wittkowski³, Marija Jelusic¹³, Jordi Anton¹⁴, Samira Khaldi-Plassart¹⁵, Alexandre Belot¹⁶, Gerd Horneff¹⁷, Seraina Palmer Sarott¹⁸, Elvira cannizzaro Schneider¹⁸, Pavla Dolezalova⁹, Angelo Ravelli¹⁹, Seza Ozen²⁰ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ³Department of Pediatric Rheumatology & Immunology, WWU Medical Center (UKM), Münster, Germany, ⁴Pediatric Rheumatology & Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Pediatrics, Division of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ⁶Department of Pediatrics, Division of Pediatric Pulmonology, Hacettepe University, Ankara, Turkey, ⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ⁸Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁹Centre for Paediatric Rheumatology and Autoinflammatory Diseases , Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, ¹⁰Department of pediatrics and Rheumatology, IRRCS Istituto G. Gaslini, Genova, Italy, ¹¹Department of pediatric rheumathology Karolinska University Hospital and Department of pediatrics, Karolinska Institute, Stockholm, Sweden, ¹²UOC Pediatria a Media Intensità di Cure, Clinica de Marchi, Milano, Italy, ¹³Department of Pediatrics, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, ¹⁴Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ¹⁵Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France, ¹⁶Hospices Civils de Lyon, Collonges au mont d'or, France, ¹⁷Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ¹⁸Paediatric Rheumatology University Children’s Hospital Zurich, Zürich, Switzerland, ¹⁹Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal Infantile Sciences (DINOGMI) University of Genoa, Italy,Scientific Direction, IRCCS Istituto Giannina Gaslini, Genova, Italy, ²⁰Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Chronic parenchymal lung disease (LD) is a new emerging severe life-threatening complication of sJIA. The number of sJIA patients with LD is apparently increasing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].